# Recovery & Rejuvenation

Source: https://onco.cc/fronts/rejuvenation/  
OnCo record `rejuvenation` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

What cancer treatment took, and whether it comes back: hair, hearing, fertility, bone, muscle, nerves, memory, the heart, skin, sexual function and the years afterwards. Recovery begins during treatment rather than after it, and structured exercise has more evidence behind it than everything sold as rejuvenation put together.

## Summary

Supportive care keeps a person well enough to get through treatment. It handles the sickness, the pain, the sore mouth and the low blood counts while treatment is happening, and when treatment stops, most of it stops too. This front asks the other question, the one that starts on the last day: what did the treatment take, and does it come back? Hair and eyebrows, hearing, fertility, bone, muscle, the nerves in the hands and feet, memory and concentration, the heart, skin and scars, sexual function, sleep, work, money, the people who were caring for you, and the body's measured biological age. That is the line. Where a measure sits on both sides of it, the record is shared with supportive care rather than written twice.

The honest one-line summary of the evidence is that exercise outperforms everything sold as rejuvenation, and it is not close. In the CHALLENGE trial, 889 people with resected colon cancer were randomised after adjuvant chemotherapy to a three-year coached exercise programme or to health-education materials; at a median follow-up of 7.9 years, disease-free survival was longer with exercise (hazard ratio 0.72, 95% CI 0.55 to 0.94), five-year disease-free survival was 80.3 against 73.9 per cent, and eight-year overall survival was 90.3 against 83.2 per cent. For fatigue, a meta-analysis of 113 studies and 11,525 participants put exercise at a weighted effect size of 0.30 and psychological therapy at 0.27, against 0.09 for drugs, which did not reach significance. No supplement, infusion, peptide or clinic programme sold for recovery has produced a result of that kind in any cancer, and most have produced no randomised result at all.

Timing is the second thing worth knowing, because most of what works has to start before the damage is done. Scalp cooling only works if it begins with the first infusion. Fertility preservation has to happen before the first dose. Prehabilitation is the weeks before an operation, not the months after. Hearing, bone and the heart are protected while the drug is being given rather than repaired years later. Dental work belongs before the first fraction of head and neck radiotherapy, because teeth do not grow back. A survivor reading this front after treatment has finished has not missed everything, but they have missed some of it, and the pages say which.

Every approach carries an evidence grade, from strong through moderate and insufficient to no-benefit and harm, because people finishing treatment are offered stem cell infusions, exosomes, unlicensed peptides, ozone, intravenous NAD+ and compounded hormone pellets at a price, usually by someone who knows what they have been through. A grade of insufficient is more use than a brochure. So is a named gap: no treatment restores the processing speed lost to chemotherapy, nothing in routine use accelerates thymic recovery in an adult, no randomised trial has shown that any survivorship screening programme reduces death from a second cancer, and no trial has tested whether moving a measured marker of biological ageing changes anything a person would notice. Those are the open problems, written down as records rather than smoothed over.

The front holds more than two hundred records: the body system by system, hair and scalp cooling, the mind and the life around it, childhood and young adult survivorship with the cohorts that document it, transplant and cell therapy, second cancers, biological ageing and the frontier of what is being tried against it, and the history of survivorship as an idea from Fitzhugh Mullan's 1985 essay to the national programmes built on it. The roadmap sets out the eras and what the next decade turns on.

## Fields

- Kind: Front
- Last checked: 2026-09-04
- Tags: survivorship; late-effects; recovery; rehabilitation; fertility; hair; exercise; rejuvenation

## Sources

- NCI: Cancer survivorship: https://www.cancer.gov/about-cancer/coping/survivorship
- NCI: Late effects of treatment for childhood cancer (PDQ): https://www.cancer.gov/types/childhood-cancers/late-effects-pdq
- Macmillan Cancer Support: After treatment: https://www.macmillan.org.uk/cancer-information-and-support/after-treatment
- Courneya et al., Structured exercise after adjuvant chemotherapy for colon cancer, the CHALLENGE trial (NEJM 2025): https://doi.org/10.1056/NEJMoa2502760
- Mullan, Seasons of survival: reflections of a physician with cancer (NEJM 1985): https://doi.org/10.1056/NEJM198507253130421
- Institute of Medicine, From Cancer Patient to Cancer Survivor: Lost in Transition (National Academies Press): https://doi.org/10.17226/11468
- NCI Office of Cancer Survivorship: statistics and graphs: https://cancercontrol.cancer.gov/ocs/statistics
- Department of Health, Living With and Beyond Cancer: Taking Action to Improve Outcomes (England, 29 March 2013): https://www.gov.uk/government/publications/living-with-and-beyond-cancer-taking-action-to-improve-outcomes

## Connected records

- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- terms: [Age, smoking and inherited predisposition: what the treatment risk is added to](https://onco.cc/terms/rejuv-second-age-smoking-and-inherited-risk/), [Alkylating agents and therapy-related myeloid neoplasms](https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/), [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/), [Bladder cancer after cyclophosphamide](https://onco.cc/terms/second-primary-bladder-after-cyclophosphamide/), [Body image after breast surgery and reconstruction](https://onco.cc/terms/body-image-after-breast-surgery/), [Bowel cancer after abdominal and pelvic radiotherapy](https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/), [Breast cancer after chest radiotherapy given young](https://onco.cc/terms/second-primary-breast-after-chest-radiotherapy/), [Choices made at the time of treatment that change the second cancer risk](https://onco.cc/terms/rejuv-second-choices-made-at-treatment/), [Cording (axillary web syndrome)](https://onco.cc/terms/cording-axillary-web-syndrome/), [Counting the people who live after cancer, and why the number is not a detail](https://onco.cc/terms/rejuv-history-counting-survivors/), [Cure is not enough: when late effects stopped being an afterthought](https://onco.cc/terms/rejuv-history-cure-is-not-enough/), [Endocrine-therapy-induced alopecia](https://onco.cc/terms/alopecia-endocrine-therapy/), [Erectile dysfunction after prostate cancer treatment](https://onco.cc/terms/erectile-dysfunction-after-prostate-cancer/), [Eyebrow and eyelash loss (madarosis)](https://onco.cc/terms/hair-brows-and-lashes/), [Financial toxicity](https://onco.cc/terms/financial-toxicity/), [From a clone in the blood to a leukaemia: what is known, and what is done](https://onco.cc/terms/rejuv-second-from-clone-to-disease/), [Graft-versus-host disease (GVHD) and graft-versus-leukaemia](https://onco.cc/terms/gvhd/), [Hair loss and scalp cooling with breast cancer chemotherapy](https://onco.cc/terms/hair-loss-and-scalp-cooling-breast/), [Hypogammaglobulinaemia and infection risk after B-cell therapies](https://onco.cc/terms/hypogammaglobulinaemia/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Lost in Transition: the 2006 report that defined survivorship care, and the care plan it invented](https://onco.cc/terms/rejuv-history-lost-in-transition/), [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Lymphoedema after breast cancer treatment](https://onco.cc/terms/breast-cancer-related-lymphoedema/), [Menopause symptoms after chemotherapy for breast cancer](https://onco.cc/terms/menopause-after-chemotherapy-breast/), [Pelvic floor muscle exercises](https://onco.cc/terms/pelvic-floor-muscle-exercises/), [Peripheral neuropathy (chemotherapy-induced)](https://onco.cc/terms/peripheral-neuropathy/), [Persistent chemotherapy-induced alopecia](https://onco.cc/terms/alopecia-persistent-chemotherapy/), [Persistent radiation-induced alopecia](https://onco.cc/terms/alopecia-radiotherapy-persistent/), [Platinum drugs and PARP inhibitors: the newer leukaemia risk](https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/), [Prehabilitation (the pre-treatment window)](https://onco.cc/terms/prehabilitation-term/), [Radiotherapy and second cancers: field, dose and age at exposure](https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/), [Regrowth after chemotherapy (chemo curls)](https://onco.cc/terms/hair-regrowth-after-chemotherapy/), [Sarcoma in the radiotherapy field, and angiosarcoma of the treated breast](https://onco.cc/terms/second-primary-sarcoma-in-the-treated-field/), [Screening survivors: where the UK, American and European answers differ](https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/), [Seasons of Survival: the 1985 essay that named the problem](https://onco.cc/terms/rejuv-history-seasons-of-survival/), [Second cancers after radiotherapy](https://onco.cc/terms/second-cancers-after-radiotherapy/), [Second cancers after treatment: what the risk is, and what is done about it](https://onco.cc/terms/rejuv-second-cancers-overview/), [Sexual function, fertility and body image after bowel cancer](https://onco.cc/terms/sex-fertility-after-bowel-cancer/), [Skin cancer after cancer treatment](https://onco.cc/terms/second-primary-skin-cancer-after-cancer-treatment/), [The founding of the National Coalition for Cancer Survivorship, and the word survivor](https://onco.cc/terms/rejuv-history-survivorship-movement/), [The National Cancer Survivorship Initiative in England, and the Recovery Package](https://onco.cc/terms/rejuv-history-ncsi-england/), [The scar on the face after skin cancer surgery](https://onco.cc/terms/facial-scar-after-skin-cancer/), [The UK very high risk breast screening protocol after chest radiotherapy](https://onco.cc/terms/rejuv-second-uk-very-high-risk-breast-screening/), [Thyroid cancer after neck radiotherapy, and whether to look for it](https://onco.cc/terms/second-primary-thyroid-after-neck-radiotherapy/), [Topoisomerase II inhibitors and the shorter latency](https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/), [Treatment-induced bone loss](https://onco.cc/terms/treatment-induced-bone-loss/), [What androgen deprivation costs: the side of hormone therapy the survival curves do not show](https://onco.cc/terms/prostate-adt-burden/), [What is not a second cancer: recurrence, metastasis and field cancerisation](https://onco.cc/terms/rejuv-second-what-is-not-a-second-cancer/)
- bottlenecks: [No randomised trial shows that any survivorship screening programme reduces death](https://onco.cc/bottlenecks/rejuv-agenda-screening-without-a-trial/), [No treatment restores the thinking that cancer treatment takes](https://onco.cc/bottlenecks/rejuv-agenda-nothing-restores-cognition/), [Nobody has tested whether reversing measured biological ageing changes anything](https://onco.cc/bottlenecks/rejuv-agenda-biological-age-as-an-untested-target/), [Nobody owns the follow-up once the oncology clinic lets go](https://onco.cc/bottlenecks/rejuv-agenda-nobody-owns-the-follow-up/), [Nothing in routine use rebuilds an adult's thymus](https://onco.cc/bottlenecks/rejuv-agenda-thymus-does-not-regrow/), [Registries count diagnoses and deaths, and not what treatment left behind](https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/), [Rehabilitation is recommended everywhere and commissioned almost nowhere](https://onco.cc/bottlenecks/rejuv-agenda-rehabilitation-not-commissioned/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The field cannot pool its own studies, because it has not agreed what to measure](https://onco.cc/bottlenecks/rejuv-agenda-no-agreed-outcome-measures/), [The newest treatments have not existed long enough for their late effects to appear](https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/)
- technologies: [A changed face and voice: body image after head and neck cancer treatment](https://onco.cc/technologies/rejuv-mind-visible-difference-head-and-neck/), [Acupuncture for chemotherapy-induced neuropathy](https://onco.cc/technologies/acupuncture-chemotherapy-neuropathy/), [Acupuncture for dry mouth after head and neck radiotherapy](https://onco.cc/technologies/acupuncture-xerostomia/), [Adolescents and young adults: a group with its own cancers, its own gap and its own needs](https://onco.cc/technologies/rejuv-ayac-distinct-group/), [After a transplant or cell therapy: what to ask for](https://onco.cc/technologies/rejuv-tx-what-to-ask-for/), [After ruxolitinib: belumosudil, axatilimab and ibrutinib in chronic GvHD](https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/), [After treatment in Australia: a stated model of survivorship care](https://onco.cc/technologies/rejuv-access-survivorship-care-australia/), [After treatment in Germany: a rehabilitation entitlement, not a leaflet](https://onco.cc/technologies/rejuv-access-survivorship-care-germany/), [After treatment in low and middle income countries: mostly nothing](https://onco.cc/technologies/rejuv-access-survivorship-care-lmic/), [After treatment in the Nordic countries: rehabilitation written into the pathway](https://onco.cc/technologies/rejuv-access-survivorship-care-nordic/), [After treatment in the UK: personalised care, and follow-up you lead yourself](https://onco.cc/technologies/rejuv-access-survivorship-care-uk/), [After treatment in the United States: the survivorship care plan, and what the trial found](https://onco.cc/technologies/rejuv-access-survivorship-care-us/), [American ginseng for cancer-related fatigue](https://onco.cc/technologies/american-ginseng-fatigue/), [Antiandrogens for hair: spironolactone, finasteride, dutasteride](https://onco.cc/technologies/hair-antiandrogens-alopecia/), [Anxiety after cancer, in survivors and in their partners](https://onco.cc/technologies/rejuv-mind-anxiety-after-cancer/), [Anxiety around scans, and what the evidence says about how often to scan](https://onco.cc/technologies/rejuv-mind-scan-anxiety/), [Asking people how they are, every week, as a treatment in its own right](https://onco.cc/technologies/rejuv-measure-epro-as-treatment/), [B-cell aplasia and low antibodies after CAR-T and bispecifics, and immunoglobulin replacement](https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/), [Balance, dizziness and falls after cancer treatment](https://onco.cc/technologies/rejuv-rehab-balance-vestibular/), [Bimatoprost for eyelash and eyebrow regrowth](https://onco.cc/technologies/bimatoprost-eyelash-regrowth/), [Blood counts that do not come back after CAR-T: ICAHT](https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/), [Body image after cancer treatment: how it is measured, what drives it, and what helps](https://onco.cc/technologies/rejuv-mind-body-image-after-cancer/), [Bone after childhood cancer: peak bone mass, osteonecrosis and what rebuilds](https://onco.cc/technologies/rejuv-paed-bone/), [Bone loss caused by cancer treatment, and what rebuilds it](https://onco.cc/technologies/cancer-treatment-bone-loss/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [Bowel function after pelvic radiotherapy](https://onco.cc/technologies/bowel-after-pelvic-radiotherapy/), [Breast cancer after chest radiotherapy in childhood, and the screening that follows](https://onco.cc/technologies/rejuv-paed-breast-after-chest-radiotherapy/), [Breast reconstruction: implant and autologous, immediate and delayed, and what women report afterwards](https://onco.cc/technologies/rejuv-recon-breast/), [BREAST-Q and the Q-portfolio: measuring what an operation left behind](https://onco.cc/technologies/rejuv-measure-breast-q/), [Breathing and exercise capacity after lung resection](https://onco.cc/technologies/rejuv-rehab-respiratory/), [Camouflage and restoration: fibres, micropigmentation, transplantation](https://onco.cc/technologies/hair-camouflage-and-restoration/), [Cancer rehabilitation: the discipline that puts function back](https://onco.cc/technologies/rejuv-rehab-cancer-rehabilitation/), [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Cardiopulmonary exercise testing: the hardest number in recovery](https://onco.cc/technologies/rejuv-measure-cardiopulmonary-exercise-testing/), [Children of a parent treated for cancer](https://onco.cc/technologies/rejuv-life-children-of-a-parent-with-cancer/), [Chronic graft-versus-host disease](https://onco.cc/technologies/gvhd-chronic-overview/), [Chronic GvHD organ by organ: skin, mouth, eyes, gut, liver, joints and genital tract](https://onco.cc/technologies/gvhd-organ-by-organ/), [Clonal haematopoiesis after cancer treatment](https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/), [Cognitive behavioural therapy for fatigue and distress](https://onco.cc/technologies/cbt-fatigue-distress/), [Cognitive behavioural therapy for insomnia (CBT-I)](https://onco.cc/technologies/cbt-insomnia-cancer/), [Compounded hormone pellets](https://onco.cc/technologies/rejuv-frontier-hormone-pellets/), [Compression, decongestive therapy and exercise for lymphoedema](https://onco.cc/technologies/lymphoedema-decongestive-therapy/), [Creams and lotions tried to prevent chemotherapy hair loss](https://onco.cc/technologies/hair-topical-prevention-agents/), [CT body composition and sarcopenia measurement](https://onco.cc/technologies/ct-body-composition-sarcopenia/), [Depression during and after cancer: the interview-based prevalence, and the care model that works](https://onco.cc/technologies/rejuv-mind-depression-after-cancer/), [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/), [Education, work and the years that were interrupted](https://onco.cc/technologies/rejuv-ayac-education-and-work/), [Employment rights with cancer in the United Kingdom](https://onco.cc/technologies/rejuv-life-employment-rights-uk/), [Employment rights with cancer in the United States](https://onco.cc/technologies/rejuv-life-employment-rights-us/), [Enhanced recovery (ERAS) and perioperative nutrition](https://onco.cc/technologies/eras-perioperative-nutrition/), [EORTC QLQ-C30: the questionnaire most cancer trials use](https://onco.cc/technologies/rejuv-measure-eortc-qlq-c30/), [Epigenetic age after cancer treatment](https://onco.cc/technologies/rejuv-age-epigenetic-clocks/), [EQ-5D: health reduced to one number, and what that number is for](https://onco.cc/technologies/rejuv-measure-eq-5d/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [Exercise is the best-evidenced thing on this front, and most survivors are not doing it](https://onco.cc/technologies/rejuv-access-exercise-programmes/), [Exosome injections](https://onco.cc/technologies/rejuv-frontier-exosome-injections/), [Extracorporeal photopheresis for graft-versus-host disease](https://onco.cc/technologies/gvhd-photopheresis/), [Facial reconstruction and facial prostheses: ears, orbits and noses](https://onco.cc/technologies/rejuv-recon-facial-prosthetics/), [FACT-G and the FACIT family: the other main questionnaire](https://onco.cc/technologies/rejuv-measure-fact-and-facit/), [Fat grafting after cancer surgery](https://onco.cc/technologies/rejuv-frontier-fat-grafting/), [Fatigue after cancer treatment: what actually works](https://onco.cc/technologies/cancer-related-fatigue-management/), [Fear that the cancer will come back: how common it is, and when it stops being ordinary worry](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence/), [Fertility in boys and young men treated for cancer, including testicular tissue banking](https://onco.cc/technologies/rejuv-paed-fertility-male/), [Fertility in girls and young women treated for cancer, including ovarian tissue freezing](https://onco.cc/technologies/rejuv-paed-fertility-female/), [Fertility-sparing hormonal treatment of early endometrial cancer](https://onco.cc/technologies/fertility-sparing-endometrial/), [Fertility, growth and what total body irradiation costs](https://onco.cc/technologies/rejuv-tx-fertility-and-growth/), [Financial toxicity and financial navigation](https://onco.cc/technologies/financial-navigation/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Frozen gloves, socks and compression for taxane nail and nerve damage](https://onco.cc/technologies/frozen-gloves-compression-taxane/), [Getting psychological help after cancer: the stepped-care model, and what is actually commissioned](https://onco.cc/technologies/rejuv-mind-access-to-psychological-care/), [Glutamine for mucositis and neuropathy](https://onco.cc/technologies/glutamine-mucositis-neuropathy/), [Going back to driving, lifting and exercise](https://onco.cc/technologies/rejuv-rehab-driving-and-exercise-return/), [Going back to work after cancer: the rates, and the programmes that change them](https://onco.cc/technologies/rejuv-life-return-to-work/), [Growth and final height after treatment in childhood, and growth hormone](https://onco.cc/technologies/rejuv-paed-growth-and-height/), [Head and neck reconstruction: the free flap, and what it gives back](https://onco.cc/technologies/rejuv-recon-head-neck/), [Hearing after platinum and cranial radiotherapy in a developing child](https://onco.cc/technologies/rejuv-paed-hearing/), [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [Heart function after anthracyclines, trastuzumab and chest radiotherapy](https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/), [Hormones, metabolism and the heart after transplant](https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/), [How chronic GvHD is diagnosed and scored: the NIH consensus criteria](https://onco.cc/technologies/gvhd-nih-consensus-criteria/), [How long it takes to diagnose cancer in a young person, and what the evidence actually says](https://onco.cc/technologies/rejuv-ayac-diagnostic-delay/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [How recovery is measured: the questionnaires behind the numbers](https://onco.cc/technologies/rejuv-measure-patient-reported-outcomes/), [Hyperbaric oxygen for late radiation injury](https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/), [Hyperbaric oxygen sold as rejuvenation](https://onco.cc/technologies/rejuv-frontier-hyperbaric-oxygen-claims/), [ICANS, and whether thinking recovers after CAR-T](https://onco.cc/technologies/rejuv-tx-icans-and-neurocognition/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it](https://onco.cc/technologies/rejuv-tx-infection-by-phase/), [Insurance, mortgages and the right to be forgotten](https://onco.cc/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/), [Intravenous NAD+ drips](https://onco.cc/technologies/rejuv-frontier-nad-infusions/), [Iron overload after transplant](https://onco.cc/technologies/rejuv-tx-iron-overload/), [Kidneys after cisplatin, ifosfamide, radiotherapy and nephrectomy in childhood](https://onco.cc/technologies/rejuv-paed-kidneys/), [Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked](https://onco.cc/technologies/rejuv-paed-late-mortality/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Limb salvage, amputation, and the rehabilitation that follows either](https://onco.cc/technologies/rejuv-recon-limb/), [Living with a stoma, and living after an amputation](https://onco.cc/technologies/rejuv-mind-body-after-stoma-and-limb-loss/), [Long-term follow-up for gene-modified cell products: fifteen years, and why](https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/), [Long-term follow-up in the United Kingdom: what a survivor is actually offered](https://onco.cc/technologies/rejuv-paed-uk-long-term-follow-up/), [Low-level light therapy (photobiomodulation) for hair](https://onco.cc/technologies/hair-photobiomodulation/), [Lymphoedema: catching it early, and the operations for it](https://onco.cc/technologies/lymphoedema-surgery-and-early-detection/), [Measuring fear of recurrence: the FCRI and its cut-off](https://onco.cc/technologies/rejuv-measure-fear-of-recurrence-inventory/), [Measuring lymphoedema: tape, bioimpedance and the quality of life scales](https://onco.cc/technologies/rejuv-measure-lymphoedema/), [Measuring memory and concentration after treatment](https://onco.cc/technologies/rejuv-measure-cognitive-function/), [Measuring muscle and fat on scans the patient already had](https://onco.cc/technologies/rejuv-measure-body-composition/), [Memory, attention and learning after treatment of a childhood cancer](https://onco.cc/technologies/rejuv-paed-neurocognitive/), [Menopause brought on by cancer treatment, and the options for it](https://onco.cc/technologies/menopause-after-cancer-treatment/), [Mesenchymal stromal cells for tissue damage](https://onco.cc/technologies/rejuv-frontier-mesenchymal-stromal-cells/), [Metformin as an anti-ageing drug after cancer](https://onco.cc/technologies/rejuv-frontier-metformin-ageing/), [Mindfulness-based stress reduction and cognitive therapy](https://onco.cc/technologies/mindfulness-based-interventions/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [Muscle and strength after treatment: sarcopenia, cachexia and what rebuilds](https://onco.cc/technologies/muscle-recovery-after-cancer-treatment/), [NAD+ precursors taken by mouth](https://onco.cc/technologies/rejuv-frontier-nad-precursors/), [Nails after chemotherapy: lifting, ridges and discolouration](https://onco.cc/technologies/nail-changes-after-chemotherapy/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Oral cryotherapy (ice chips) to prevent mucositis](https://onco.cc/technologies/oral-cryotherapy-mucositis/), [Ovarian function after chemotherapy: who recovers, and when](https://onco.cc/technologies/ovarian-function-after-chemotherapy/), [Ozone therapy](https://onco.cc/technologies/rejuv-frontier-ozone-therapy/), [Partners and relationships after cancer: what the divorce data actually show](https://onco.cc/technologies/rejuv-life-partners-and-intimacy/), [Pelvic floor rehabilitation after prostate and rectal surgery and after pelvic radiotherapy](https://onco.cc/technologies/rejuv-rehab-pelvic-floor/), [Photobiomodulation (low-level laser) for oral mucositis](https://onco.cc/technologies/photobiomodulation-mucositis/), [Platelet-rich plasma for hair after cancer treatment](https://onco.cc/technologies/hair-platelet-rich-plasma/), [Platelet-rich plasma for survivors](https://onco.cc/technologies/rejuv-frontier-platelet-rich-plasma/), [Post-traumatic growth: what people report, and what the measurement actually captures](https://onco.cc/technologies/rejuv-mind-post-traumatic-growth/), [Post-traumatic stress after cancer: what is measured, and how much of it is measurement](https://onco.cc/technologies/rejuv-mind-traumatic-stress-after-cancer/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Preventing graft-versus-host disease, and what prevention costs](https://onco.cc/technologies/gvhd-prophylaxis/), [PRO-CTCAE: side effects graded by the person having them](https://onco.cc/technologies/rejuv-measure-pro-ctcae/), [PROMIS: the item banks that let a short questionnaire be precise](https://onco.cc/technologies/rejuv-measure-promis/), [Prospective surveillance: looking for the problem before it becomes a disability](https://onco.cc/technologies/rejuv-rehab-prospective-surveillance/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [Psycho-oncology and distress screening](https://onco.cc/technologies/psycho-oncology/), [Quality of life after transplant and cell therapy](https://onco.cc/technologies/rejuv-tx-quality-of-life/), [Rapamycin and mTOR inhibition for ageing](https://onco.cc/technologies/rejuv-frontier-rapamycin-ageing/), [Rebuilding an immune system: the timeline, lineage by lineage](https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/), [Rebuilding the immune system after treatment](https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/), [Recovery after pelvic exenteration](https://onco.cc/technologies/rejuv-recon-pelvic-exenteration/), [Referral to rehabilitation: the service most people who need it never see](https://onco.cc/technologies/rejuv-access-rehabilitation-referral/), [Relaxation training and guided imagery](https://onco.cc/technologies/relaxation-guided-imagery/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Revaccination after transplant: the schedules, and where the UK and the US differ](https://onco.cc/technologies/rejuv-tx-revaccination/), [Scalp care during and after cancer treatment](https://onco.cc/technologies/scalp-care-cancer-treatment/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Scars, stiffness and contracture: shoulders, necks and jaws](https://onco.cc/technologies/rejuv-rehab-scar-contracture/), [Scrambler therapy (Calmare) for chemotherapy nerve pain](https://onco.cc/technologies/scrambler-therapy/), [Screening for distress: what the thermometer can and cannot do](https://onco.cc/technologies/rejuv-mind-distress-screening/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/), [Second cancers after childhood cancer: the risk by treatment, and why it is falling](https://onco.cc/technologies/rejuv-paed-second-cancers/), [Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says](https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/), [Senescent cells and p16 after chemotherapy](https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Senolytics and senescence-directed therapy](https://onco.cc/technologies/senescence-targeting/), [Services built for teenagers and young adults, and what the national evaluation found](https://onco.cc/technologies/rejuv-ayac-services/), [Sexual function and intimacy after cancer, for both sexes](https://onco.cc/technologies/sexual-function-after-cancer/), [Skin during and after radiotherapy: dressings, steroids and what lasts](https://onco.cc/technologies/radiation-skin-recovery/), [Sleep after cancer: how common insomnia is, how long it lasts, and the treatment that works](https://onco.cc/technologies/rejuv-mind-sleep-after-cancer/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Sleeping tablets after cancer: what they do and what they do not](https://onco.cc/technologies/rejuv-mind-sleeping-tablets-after-cancer/), [Stem cell clinics and stem cell tourism](https://onco.cc/technologies/rejuv-frontier-stem-cell-tourism/), [Stoma reversal after rectal cancer surgery: who gets the bowel joined up again](https://onco.cc/technologies/rejuv-recon-stoma-reversal/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/), [Supplements sold for hair growth after cancer treatment](https://onco.cc/technologies/hair-supplements-marketed/), [Survival after transplant, and why the curve never quite rejoins the population](https://onco.cc/technologies/rejuv-tx-survival-after-transplant/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Swallowing therapy around head and neck radiotherapy](https://onco.cc/technologies/rejuv-rehab-swallowing/), [Tai chi and qigong](https://onco.cc/technologies/tai-chi-qigong/), [Teeth, jaws and facial growth after treatment in childhood](https://onco.cc/technologies/rejuv-paed-teeth-and-face/), [Telomere length after treatment](https://onco.cc/technologies/rejuv-age-telomere-length/), [Testosterone after cancer treatment in men](https://onco.cc/technologies/testosterone-after-cancer-treatment/), [The biological age test you can buy, and whether to buy one](https://onco.cc/technologies/rejuv-measure-consumer-biological-age-tests/), [The carer's own recovery: what is known about the person who is not the patient](https://onco.cc/technologies/rejuv-life-carers/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The cumulative dose that decides whether it comes back](https://onco.cc/technologies/rejuv-recovery-cumulative-dose/), [The devices that do the restoring, and who pays for them](https://onco.cc/technologies/rejuv-rehab-assistive-devices/), [The exercise prescription after cancer: the dose the guidelines state](https://onco.cc/technologies/exercise-prescription-after-cancer/), [The gap between the rehabilitation people need and the rehabilitation they are offered](https://onco.cc/technologies/rejuv-rehab-provision-gap/), [The handover from children's to adult services, where follow-up falls away](https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/), [The lungs after transplant: bronchiolitis obliterans syndrome](https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/), [The pituitary, puberty and the hypothalamic axis after cranial radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-pituitary-and-puberty/), [The questionnaires that were never returned, and the people never asked](https://onco.cc/technologies/rejuv-measure-missing-data-and-who-is-not-asked/), [The word survivor, and why the vocabulary is not a detail](https://onco.cc/technologies/rejuv-mind-the-word-survivor/), [Thinking and memory after cancer treatment: what is measurable, and what helps](https://onco.cc/technologies/cognitive-impairment-after-cancer-treatment/), [Treating fear of recurrence: the randomised trials, their effect sizes, and where the treatment is available](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence-treatment/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [Unlicensed peptides sold for recovery](https://onco.cc/technologies/rejuv-frontier-unlicensed-peptides/), [Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees](https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/), [Voice after the larynx is removed](https://onco.cc/technologies/rejuv-recon-voice-after-laryngectomy/), [Walking, gripping and standing up: the tests that take five minutes](https://onco.cc/technologies/rejuv-measure-functional-tests/), [Wearables and step counts: measuring what someone actually does](https://onco.cc/technologies/rejuv-measure-wearables-and-step-counts/), [What a difference has to be before a person would notice it](https://onco.cc/technologies/rejuv-measure-minimally-important-difference/), [What a prehabilitation programme actually contains, and how long it needs](https://onco.cc/technologies/rejuv-rehab-prehabilitation-programme/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/), [What has actually been implemented since those trials, and what has not](https://onco.cc/technologies/rejuv-measure-epro-implementation/), [What recovery costs in the rest of the world](https://onco.cc/technologies/rejuv-access-what-it-costs-elsewhere/), [What recovery costs in the UK, and what it does not](https://onco.cc/technologies/rejuv-access-what-it-costs-uk/), [What recovery costs in the United States](https://onco.cc/technologies/rejuv-access-what-it-costs-us/), [What the randomised trials of prehabilitation found, operation by operation](https://onco.cc/technologies/rejuv-rehab-prehabilitation-evidence/), [When steroids fail: ruxolitinib for steroid-refractory GvHD](https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/), [Where rehabilitation is commissioned, and who misses out](https://onco.cc/technologies/rejuv-rehab-commissioning-inequity/), [Who gets told about fertility before treatment, and who does not](https://onco.cc/technologies/rejuv-access-fertility-preservation/), [Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered](https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/), [Who misses out on recovery care, measured](https://onco.cc/technologies/rejuv-access-who-misses-out/), [Wigs, cranial prostheses and head coverings](https://onco.cc/technologies/wigs-cranial-prosthesis/)
- journals: [Journal of cancer survivorship](https://onco.cc/journals/journal-of-cancer-survivorship/)
- ideas: [A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy](https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/), [Agree what to measure, so the next systematic review can pool rather than narrate](https://onco.cc/ideas/idea-rejuv-core-outcome-set-for-late-effects/), [Ask whether survivorship screening saves lives, using registry-based randomisation](https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/), [Default fertility preservation referral for every patient under 40 before treatment](https://onco.cc/ideas/idea-acc-default-fertility-preservation-referral/), [Enrol every new systemic therapy into a registry linkage that will still report in thirty years](https://onco.cc/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/), [Fertility preservation offered and funded by default before gonadotoxic treatment](https://onco.cc/ideas/idea-moon-fertility-preservation-default/), [Find out whether an adult thymus can be made to work again, with an endpoint a clinician would act on](https://onco.cc/ideas/idea-rejuv-thymic-regeneration-in-adults/), [Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen](https://onco.cc/ideas/idea-moon-hair-preservation-for-all/), [Fund structured exercise after colon cancer surgery as a treatment, because a randomised trial says it works as well as a drug](https://onco.cc/ideas/idea-crc-exercise-as-a-funded-treatment/), [Give survivorship interventions a shared control arm](https://onco.cc/ideas/idea-rejuv-survivorship-platform-trial/), [Make the treatment exposure record machine-readable, so surveillance can be computed](https://onco.cc/ideas/idea-rejuv-exposure-record-a-machine-can-read/), [Measure and treat chemo brain with objective digital cognitive testing](https://onco.cc/ideas/idea-moon-cognitive-toxicity-programme/), [Multimodal prehabilitation for older patients before major cancer surgery](https://onco.cc/ideas/idea-acc-prehabilitation-older-surgery/), [One-two punch: clear senescent cells after chemotherapy](https://onco.cc/ideas/idea-senolytics-after-chemo/), [Prospective arm-volume surveillance to catch and reverse lymphoedema early](https://onco.cc/ideas/idea-acc-lymphoedema-prospective-surveillance/), [Protect hearing from cisplatin in adults as we now do in children](https://onco.cc/ideas/idea-moon-hearing-protection-cisplatin/), [Put a biological-age marker in a trial that also measures something a person would notice](https://onco.cc/ideas/idea-rejuv-biological-age-as-a-randomised-endpoint/), [Trials of structured cognitive rehabilitation for cancer-related cognitive impairment](https://onco.cc/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/), [Write a rehabilitation prescription at the end of treatment, and fund it like a drug](https://onco.cc/ideas/idea-rejuv-rehabilitation-prescription-at-discharge/)
- drugs: [Belumosudil](https://onco.cc/drugs/belumosudil/)
- collections: [British Childhood Cancer Survivor Study (BCCSS)](https://onco.cc/collections/bccss/), [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/), [Look Good Feel Better](https://onco.cc/collections/look-good-feel-better/), [PanCareSurFup and the European survivor cohorts](https://onco.cc/collections/pancaresurfup/), [St Jude Lifetime Cohort Study (SJLIFE)](https://onco.cc/collections/sjlife/), [The Little Princess Trust](https://onco.cc/collections/little-princess-trust/), [Wigs for Kids](https://onco.cc/collections/wigs-for-kids/)
- trials: [AlloCare: a stepped-care late-effects service after allogeneic transplant](https://onco.cc/trials/rejuv-trial-allocare/), [AMICO: aerobic or resistance exercise to improve outcome in metastatic colorectal cancer](https://onco.cc/trials/rejuv-trial-amico/), [CanWork: an occupational therapy programme to help women return to work after breast cancer](https://onco.cc/trials/rejuv-trial-canwork/), [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/), [EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage](https://onco.cc/trials/rejuv-trial-ex-cipn/), [PROFFi: fisetin and exercise to prevent frailty in breast cancer survivors](https://onco.cc/trials/rejuv-trial-proffi/)
- people: [Ellen L. Stovall](https://onco.cc/people/ellen-stovall/), [Fitzhugh Mullan](https://onco.cc/people/fitzhugh-mullan/)
- companies: [Dignitana](https://onco.cc/companies/dignitana/), [Luminate Medical](https://onco.cc/companies/luminate-medical/), [Paxman](https://onco.cc/companies/paxman/)

---
JSON: https://onco.cc/api/v1/entities/rejuvenation.json